Dendritic cells (DCs) are critical for instructing immune responses toward inflammatory or anti-inflammatory status. Heme oxygenase-1 (HO-1) is known for its cytoprotective effect against oxidative stress and inflammation, suggesting its immune regulatory role in allergic lung inflammation. HO-1 has been implicated in affecting DC maturation; however, its role in DC-mediated T-cell differentiation is unclear. In this study, we demonstrated that HO-1-expressing bone marrow-derived dendritic cells (BM-DCs) displayed tolerogenic phenotypes, including their resistance to lipopolysaccharide (LPS)-induced maturation, high level expression of IL-10, and low T-cell stimulatory activity. In addition, HO-1-expressing DCs were able to induce antigen-specific Foxp3 + regulatory T cells (Treg) differentiation in vitro and in vivo. Also, HO-1-expressing DCs modulated the severity of lung inflammatory responses in two murine models of airway inflammation. This study provided evidence supporting the role of HO-1-expressing DCs in tolerance induction and as a potential therapeutic target for allergic asthma as well as other inflammatory diseases.
Introduction
The lungs are the important organ in contact with external stimuli, including allergens, air pollutants, or infectious agents. Upon stimulation, heme oxygenases-1 (HO-1) activity in the lung represents an important defense mechanism. HO-1 degrades heme into free divalent iron, carbon monoxide and biliverdin, while these metabolites are known for the cytoprotective and anti-inflammatory effects in various disease contexts, including allogenic graft transplantation [1], pregnancy [2] , and neutrophilic airway inflammation [3] . Recent studies of HO-1 on lung inflammation and injury clearly show the cytoprotective effect against oxidative stress and lung inflammation by reducing neutrophils infiltration from bone marrow [4, 5] . Understanding the mechanism of HO-1 system in DC's function may help to design antigen (Ag)-specific therapeutic strategy for lung diseases. Asthma is a complicated chronic inflammatory disease, which includes Th2-mediated eosinophilic inflammation and Th17-mediated neutrophilic inflammation [6, 7] . Dendritic cell (DC) is the key regulatory cell type for directing Th2 and Th17 differentiation and for the development of allergic diseases [8] . In addition, DCs with tolerogenic property may promote Foxp3 + regulatory T cells (Treg) differentiation for immune suppression by secreting TGF-β or expressing inhibitory receptors, such as programmed death ligand 1 (PD-L1) [9] [10] [11] . Thus, clarifying the modulatory effect of HO-1 expression in DCs may facilitate the development of Ag-specific tolerance in different types of asthma. Ag-specific tolerance mediated by Tregs is important for maintaining homeostasis, preventing autoimmunity as well as hypersensitivity. Two subsets of CD4 + Tregs have been classified as natural and adaptive Tregs [12, 13] . Natural occurring Tregs develop during normal T-cell maturation in the thymus [14, 15] , while adaptive Tregs are developed throughout the course of the immune response in vivo. Although HO-1 induction is associated with elevation of Treg numbers in the context of intestinal inflammation and pregnancy in mice [2, 16] ; however, questions remain to be addressed as to whether HO-1 is involved in the development of Tregs through modulating DC differentiation or activity.
Mechanisms that underlie anti-inflammatory effect of HO-1 in the pulmonary inflammation remain largely unknown. Thus, we investigated the mechanisms that contribute to the protective role of HO-1 in murine models of airway lung inflammation. We studied the effect of HO-1 expression on DC differentiation and function and the consequent Ag-specific adaptive Treg differentiation.
Materials and Methods

Experimental animals
All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee of the Kaohsiung Medical University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Kaohsiung Medical University (Permit Number: 95162). Female BALB/cByJNarl, and DO11.10 mice, aged 6-8 weeks, were obtained from National Laboratory Animal Center and female C.Cg-Foxp3 tm2Tch /J (Foxp3 EGFP ) mice from Jackson Lab. All mice were maintained by the Animal Center of Kaohsiung Medical University in a pathogen-free facility. All mice were provided with water and food ad libitum. Animals were anesthetized with intraperitoneal injection of pentobarbital (50-70 mg/kg) before intravenous and intratracheal injections and at sacrifice. The health and condition of all mice in this study were monitored daily prior to sacrifice, and all mice have no clinical signs of ill health. If the mice would have developed signs of severe illness, including weight loss, shortness of breath, and low appetite, they would have been euthanized immediately.
BM-DCs generation and treatment
Bone marrow cells were cultured with recombinant murine GM-CSF (125 U/ml, Pepro Tech Inc., Rocky Hill, NJ) and 2-mercaptoethanol (50 μM) for 6 days as described previously [17] . Day-6 BM-DCs were further purified with anti-mouse CD11c magnetic beads (Miltenyi Biotec, Sunnyvale, Calif., USA) according to the manufacturer's instructions. Purified BM-DCs were treated with different concentrations (0-50 μM) of DMSO, Zinc protoporphyrin-IX (ZnPP), Tin protoporphyrin-IX-chloride (SnPP) or cobalt (III) protoporphyrin-IX-chloride (CoPP) for 2 hours and replaced with fresh medium for further 14 hours. LPS (1 μg/ml, Escherichia coli O127:B8; Sigma-Aldrich, St. Louis, Mo., USA) was then added as stimuli and cultured for 24 hours. The cells were harvested for phenotypic analysis, western blotting or the analysis of T-cell responses, and supernatants collected for cytokine determination by ELISA (eBioscience, Ireland, UK). The phenotype and purity of BM-DCs were analyzed by flow cytometry (LSR II; BD Biosciences, San Diego, Calif., USA) for the expression of CD11c (G418), MHC class II (M5/114.15.2), CD40 (1C10), CD80 (16-10A1) and CD86 (GL1).
Western blotting
The treated BM-DCs were lysed in the lyses buffer (3% sodium dodecyl sulfate, 1.67 M urea and 2.7% 2-mercaptoethanol), resolved in a 10% SDS-polyacrylamide gel and electro-transferred onto Hybond-C extra membranes (Amersham, Piscataway, N.J., USA). The membranes were blocked with TBST (50 mM Tris-HCl, 0.15 M NaCl and 0.05% Tween 20) containing 2.5% non-fat milk at room temperature for 1 hour and then incubated with primary antibodies at 4˚C overnight. Bound antibodies were detected with peroxidase-labeled secondary antibodies at room temperature for 2 hours, and blots were developed by Western Lightning chemiluminescence reagent (Perkin Elmer, Waltham, Mass., USA). Blots were washed with TBST four times in-between steps. Primary antibodies in these experiments included those for HO-1 and β-actin (Millipore, Billerica, Mass., USA) [18, 19] .
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Statistical analysis
Statistical comparisons of data among groups of control and treated BM-DCs were performed with the nonparametric Mann-Whitney U test. Values of p < 0.05 were considered significant. All statistical tests were performed by SPSS for Windows, version 13.0. (SPSS Inc., Chicago, Ill., USA).
Results
HO-1 induction inhibits LPS-induced maturation and proinflammatory activity in BM-DCs
HO-1 protein level was initially analyzed when BM-DCs were treated with CoPP in various concentrations as CoPP is widely used as HO-1 inducer in vitro and in vivo. SnPP or ZnPP, two analogs of CoPP, were used as negative controls. We observed that CoPP treatment significantly increased HO-1 protein expression in BM-DCs in a concentration-dependent manner regardless of LPS stimulation (S1 Fig). Instead, SnPP did not have effect on HO-1 expression but had higher toxicity to BM-DCs than CoPP (data not shown).
To evaluate the effect of HO-1 expression on DC differentiation, we analyzed the maturation status in BM-DCs. The results showed that induction of HO-1 expression by CoPP significantly inhibited the expression levels of CD40, CD80, CD86 but not MHC class II in BM-DCs in response to LPS (Fig 1A and 1B) . In addition, CoPP-conditioned BM-DCs significantly secreted more anti-inflammatory cytokine IL-10 but much less inflammatory cytokines, IL-12, IL-23, IL-6, and TNF-α (Fig 1C) than control cells in a concentration-dependent manner. These data showed that HO-1-expressing DCs displayed an anti-inflammatory phenotype, suggesting their poor stimulatory activity in T-cell responses.
CoPP-conditioned DCs display tolerogenic phenotype
Next, we evaluated the effect of HO-1 expression on DCs in their T-cell stimulatory activity. As shown in Fig 2A, CoPP-treated BM-DCs induced significantly lesser degree of the allogenic T-cell proliferative response compared to the control cells. In addition, OVA 323-339 -pulsed BM-DCs treated with different concentrations of CoPP induced less DO11.10 CD4 + T cell proliferation ( Fig 2B) as well as IL-13 and IFN-γ secretion (Fig 2C and 2D ) as compared to the control. Taken together, these data suggested HO-1-expressing DCs may display tolerogenic phenotypes, including their semi-mature phenotype, poor T-cell stimulatory activity, high anti-inflammatory cytokine IL-10 production as well as low proinflammatory cytokine pattern.
HO-1 CoPP-conditioned DCs promote adaptive Treg differentiation
Considering that HO-1-expressing DCs may have tolerogenic properties, we further analyzed the expression levels of tolerance-associated molecules, including PD-L1, PD-L2 and inducible costimulator ligand (ICOSL) [20, 21] in CoPP-treated BM-DCs. We observed that CoPP treatment significantly enhanced the expression of PD-L1, but not PD-L2, and ICOSL molecules in BM-DCs (Fig 3A and 3B) Fig  4A) . Furthermore, intratracheal administration was also used to examine the in vivo function of HO-1-expressing DCs. As shown in Fig 4B, ) in local lymph nodes of lungs were significantly higher in mice treated with CoPPtreated BM-DCs than those treated with control cells. These data thus demonstrated that HO-1-expressing BM-DCs were able to promote Ag-specific adaptive Treg differentiation in vivo.
CoPP treatment suppresses DC-mediated airway inflammation in vivo
To analyze the in vivo function of HO-1-expressing DCs, airway inflammation was also induced by DCs in two different administration ways. First, transfer of BM-DCs intravenously for inducing neutrophil-dominated lung inflammation was examined, and the results showed (Fig 5) . In addition, intratracheal injection of BM-DCs also mediated both eosinophil and neutrophil infiltrated lung inflammation ( Fig  6A) , while CoPP-treated BM-DCs induced a lesser degree of inflammation with low eosinophil infiltration as well as IL-13 expression when compared to vehicle controls (Fig 6B and 6D) . Importantly, the number and frequency of CD4 + Foxp3 + Tregs in BALFs were also significantly higher in CoPP group than control group (Fig 6C) . Taken together, these data suggested HO-1 expression in DCs may suppress airway inflammation through its ability in promoting adaptive Treg differentiation.
Discussion
It has been shown that pharmacologic HO-1 induction mediates the anti-inflammatory effects in several models of inflammatory diseases, including asthma [3] and transplantation [22] ; however, the interaction of HO-1-expressing DCs and CD4 + CD25 + Tregs remains unclear.
This is the first study, to the best of our knowledge, to provide evidence showing that HO-1-expressing DCs are able to induce Ag-specific Foxp3 + Treg differentiation and modulate the severity of lung inflammatory responses in vivo. This study provides evidence demonstrating the tolerance-inducing ability of HO-1-expressing DCs, which may offer an experimental basis for the design of therapeutic strategy for allergic asthma as well as other inflammatory diseases.
The detailed molecular mechanisms involved in Treg differentiation induced by HO-1-expressing DCs are largely unknown. This study showed that DCs with HO-1 induction expressed low levels of co-stimulatory molecules (CD40, CD80, CD86), and secreted a high level of IL-10 as well as low levels of IL-12 and IL-23, suggesting the tolerogenic properties of HO-1-expressing DCs. Importantly, these semi-mature DCs with HO-1 induction expressed an increased level of PD-L1. PD-L1 has been reportedly to be critical to the induction of contact-dependent Tregs by vitamin D3-treated human monocyte-derived DCs [23] . The role of HO-1 in regulating PD-L1 expression and in Foxp3 + Treg differentiation needs to be further investigated.
Since CoPP can effectively induce tolerogenic DCs, we used Foxp3-EGFP reporter mice to demonstrate the effect of CoPP-treated DCs on adaptive Treg expansion or conversion. It is well known that DCs secrete TGF-β to promote Treg differentiation [24, 25] , whereas TGF-β/ IL-6 or IL-23 are known to promote proinflammatory Th17 development [26, 27] . In our study, we found that CoPP treated BM-DCs showed similar levels of TGF-β secretion but decreased IL-6 and IL-23 expression, suggesting that CoPP treated DCs may promote adaptive Treg instead of Th17 differentiation.
HO-1 is not only expressed in DCs but also in pulmonary endothelial and epithelial cells as well as alveolar macrophages [28] . Pharmacologic HO-1 induction may mediate anti-inflammatory status through coordinated contribution from several HO-l-expressing cell types; however, among these cell types, only DC has the ability to mediate Ag-specific tolerance in several different mechanisms. First, this study showed that HO-1-expressing DCs can promote Agspecific adaptive Treg differentiation, at least in part, through PD-L1. Second, IL-10 secreted by HO-1-expressing DCs at high level may enhance type 1 Treg (Tr1) differentiation, as Tr1 has a critical role in controlling peripheral tolerance [29, 30] . Third, HO-1-expressing DCs lost their ability to secrete IL-12 and IL-23, suggesting the inability to mediate Th1 and Th17 responses, respectively. Taken together, this study suggests that induction of HO-1 expression in Ag-bearing DCs can potentially be used to generate Ag-specific tolerance as a cellular therapy for allergic or autoimmune diseases.
In addition to their direct promoting activity on Treg differentiation, HO-1-expressing DCs may act on Ag-specific B cells to affect Treg differentiation in vivo as well. It has been demonstrated that Ag delivery to CD8α -DCs in the marginal zone of mice drives B cells to undergo robust antibody responses to a T cell-dependent Ag [31] . This subset of DCs may uptake Ag by macropinocytosis and transfer it to specific B cells [32] . In addition, B cells can induce T-cell tolerance via different mechanisms, including their ability to secret IL-10 [33] . It suggests, therefore, that HO-1-expressing DCs may promote adaptive Treg differentiation Two previous studies as well as our study have observed that HO-1 induction after CoPP treatment of BM-DCs inhibits LPS-mediated maturation [34, 35] . However, there are some conflicting findings among these studies and the present results. Chauveau et al. showed that HO-1 expression also conserves IL-10 expression in rat BM-DCs and human monocyte derived DCs [34] . Consistent with this finding, we demonstrated that CoPP treatment significantly increased IL-10 as well as PD-L1 protein expression of BM-DCs in BALB/c mice. However, in contrast to our results, Mashreghi et al. observed that CoPP treatment suppresses the IL-10 protein as well as PD-L1 mRNA expression in BM-DCs from C57BL/6 mice [35] . The observed discrepancies concerning the expression of tolerance-associated molecules (IL-10 and PD-L1) in these studies might be attributable to species-specific differences. Furthermore, it would be worthy investigating the HO-1 requirement in DC-mediated adaptive Treg differentiation as Mashreghi et al. has demonstrated that inhibition of DC maturation by CoPP does not require HO-1.
In the present study, two models were used for testing the ability of HO-1-expressing DCs on adaptive Treg differentiation; however, different outcomes were noted when two different models were tested. Two possible, but not mutually exclusive, reasons could account for the difference. First, as shown in the present study (Fig 4B) and the previous study [36] , intratracheally injected DCs primarily activate and instruct T-cell differentiation in local draining lymph nodes, while DCs delivered intravenously not only accumulate in the lungs and draining lymph nodes, but also disseminate into other organs, such as the spleen ( [37] , Fig 4A) , the latter of which may suggest the possibility of systemic DC's priming effect on Ag-specific T cell response. Thus, the Ag-induced lung inflammation could be regulated with different kinetics in these two different models of cell transfer. The other possible explanation is the distinct mechanism of action mediated through the use of different models. Ag-specific Tregs induced by intratracheal administration of DCs may predominately act through cell-cell contact dependent mechanism, leading to increased Treg number and frequency noted in the BALFs (Fig 6B  and 6C) , while the increased frequency of Ag-specific Treg cells induced by intravenous DC transfer may be manifested primarily in local lymph nodes, but not in the BALFs (Fig 5B and  5C) . Consequently, the expression of IL-10 is logically expected to show differences in kinetics and tissue locations. Further detailed and comprehensive kinetic analysis is required to properly address these possibilities. Our current study would provide a foundation needed for further investigation.
GM-CSF exhibits pleiotropic activities on multiple cell types and is considered as an inflammatory as well as an anti-inflammatory molecule [38, 39] . Similar to the effect of HO-1, GM-CSF promotes tolerogenic DC differentiation and subsequent adaptive Treg differentiation [40] . However, HO-1 seems not to be involved in the GM-CSF-mediated tolerance, because GM-CSF-differentiated BM-DCs did not express detectable HO-1 protein regardless of LPS stimulation (S1 Fig), but promoted the differentiation of Foxp3 + adaptive Treg in the presence of TGF-β (Fig 3D) . Whether GM-CSF and HO-1 act, simultaneously or independently, on adaptive Treg differentiation still needs to be further studied. In summary, we demonstrated, for the first time, that the tolerogenicity of HO-1-expressing DCs may instruct Ag-specific adaptive Treg differentiation, suggesting the potential therapeutic strategy for allergic asthma and other inflammatory diseases. 
